(DTIL) – Corporate News
-
Precision BioSciences (DTIL) Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
-
Precision BioSciences (DTIL) Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to DTIL Stock Lookup